A histopathologic diagnosis of prostate cancer is the discernment of whether there is a cancer in the prostate, as well as specifying any subdiagnosis of prostate cancer if possible. The histopathologic subdiagnosis of prostate cancer has implications for the possibility and methodology of any subsequent Gleason scoring. ^[1] The most common histopathological subdiagnosis of prostate cancer is acinar adenocarcinoma, constituting 93% of prostate cancers. ^[2] The most common form of acinar adenocarcinoma, in turn, is "adenocarcinoma, not otherwise specified", also termed conventional, or usual acinar adenocarcinoma. ^[3]

Contents

• Sampling
• Subdiagnoses - overview
• Acinar adenocarcinoma
• Microscopic characteristics
• Intraductal carcinoma
• Further workup
• Notes
• Reference list
• Sources

Sampling

The main sources of tissue sampling are prostatectomy and prostate biopsy.^{[ citation needed ]}

Subdiagnoses - overview

Subdiagnosis		Relative incidence		Image	Microscopic characteristics	Immunohistochemistry	Gleason scoring
		Core biopsy	Radical prostatectomy
Acinar adenocarcinoma - 93% [2]	Adenocarcinoma (not otherwise specified/ conventional/ usual acinar) [3]	77% [notes 2]	54% [notes 2]		Collagenous micronodules [4] Glomerulations [4] Further information in section below May be mixed with other subdiagnoses.	Tumorous glands: 34βE12- and p63- [2] (+ in adjacent benign glands) [2] AMACR+ (- in adjacent benign glands) [2] PSA+ (>10 ng/ml) in 60% of cases [2]	As usual
	Foamy gland carcinoma	17% [5] [notes 1]	13–23% [5] [notes 1]		Abundant foamy cytoplasm [1] Nuclei may be small and pyknotic - benign-looking [1] Infiltrative pattern	Foamy cells: PSA+ and CD68− [1] AMACR+ in 68% of cases [1]	Based on architecture, discounting foamy cytoplasms [1]
	Atrophic carcinoma	2% [5] [notes 3]	16% [5] [notes 3]		Glands lined by cells with scant cytoplasm, resembling atrophy [1] Infiltrative growth [1] Usually admixed with non-atrophic components [1]	Tumorous glands: 34βE12- and p63- [1] AMACR+ in 70% of cases [1]	As usual [1]
	Pseudohyperplastic carcinoma	2% [5]	11% [5]		Large-sized or dilated glands [1] Branching and papillary infolding [1] Tall columnar cells [1] Abundant pale to slight granular luminal cytoplasm [1] Nuclei towards basement membrane [1]	Tumorous glands: 34βE12- and p63- [1] AMACR+ in 70–83% of cases [1]	3+3=6 [1]
	Microcystic carcinoma		11% [5]		Cystic dilatation and rounded expansion of malignant glands [6] Lined by flat cells [6] Intraluminal crystalloids, and wispy blue intraluminal mucin [6]	34βE12- and p63- [6] AMACR+ [6]	On (usually) adjacent acinar adeocarcinoma [6]
	PIN-like	1.3% [7]			Glands lined by ≥2 layers of malignant cells [1] May resemble flat or tufted high-grade PIN, but lacks basal cells [1]	Tumorous glands: 34βE12- and p63- [1]	Not recommended [1]
Non acinar (or mixed acinar/ non-acinar) adenocarcinoma	Ductal adenocarcinoma	3% to 12.7% [8] [notes 1]			Large glands and papillary formations, lined by tall columnar cells, often pseudostratified [1] Papillary, cribriform, individual glands, or solid variants [1] Cytoplasm usually amphophilic [1] Nuclei are large and hyperchromatic, with prominent nucleoli [9]	AMACR+ in 77% of cases [1] Usually negative for basal cells stains [1]
	Intraductal adenocarcinoma	2.8% [10]		H&E and CK5/6	Carcinoma cells spanning entire lumen of ducts and acini [11] At least focal preservation of the basal cell layer [11]	PSA+ [10] AMACR+ [10] Basal cell markers+ [10]
	Urothelial carcinoma	0.7 to 2.8% [12]			Umbrella cells are usually present in low-grade tumors [13] Frequently branching fibrovascular cores [13] Frequently fusing of papillae [13]		Not recommended [1]
	Small-cell carcinoma	0.3–2% [14] [15] [notes 1]			Small blue cells with scant cytoplasm [1] High nucleus/cytoplasm ratio [1] "salt and pepper" chromatin [1] Nuclear molding [1] Necrosis of single cells, or geographic [1] Smearing artifacts [1] Half of cases have usual acinar components [1]
	Mucinous adenocarcinoma	0.2% [12]			≥25% of tumor shows extracellular mucin [1] Intraluminal mucinous material does not qualify [1] No extraprostatic origin found [1]	Tumorous glands: 34βE12- and p63- [1] PSA+ and CK8/18+ [1]	4+4=8 for irregular cribriform glands floating in mucin. [1]
	Signet-ring adenocarcinoma	0.02% [16]			≥25% of tumor shows signet-ring cells (widely infiltrative cells with optically clear vacuoles displacing the nuclei) [1]	Tumorous glands: 34βE12- and p63- [1] PSA+ [1]	Not recommended [1]
	Basal-cell carcinoma	0.01% [17]			Basaloid tumor: Scant cytoplasm [1] High nucleus/cytoplasm ratio [1] Irregular or angulated nuclei [1] Euchromatic [1] May have nuclear and cytoplasmic micro-vacuolation [1] Infiltration of adjacent parenchyma [1] BCC-pattern: Variably sized solid nests, cords, or trabeculae [1] Peripheral palisading [1]	p63+ [1] HMCK(34βE12)+ [1] Typically CK20−/CK7+, but CK7− in pure solid basal cell nests [1] Bcl-2+, strongly and diffusely [1] Ki-67 nuclear staining in >20% [1]	Not recommended. [1]

In uncertain cases, a diagnosis of malignancy can be excluded by immunohistochemical detection of basal cells (or confirmed by absence thereof), ^[4] such as using the PIN-4 cocktail of stains, which targets p63, CK-5, CK-14 and AMACR (latter also known as P504S).

Other prostate cancer tumor markers may be necessary in cases that remain uncertain after microscopy.

Acinar adenocarcinoma

These constitute 93% of prostate cancers. ^[2]

Intraductal carcinoma

Intraductal carcinoma of the prostate gland (IDCP), which is now categorised as a distinct entity by WHO 2016, includes two biologically distinct diseases. IDCP associated with invasive carcinoma (IDCP-inv) generally represents a growth pattern of invasive prostatic adenocarcinoma while the rarely encountered pure IDCP is a precursor of prostate cancer. ^[20] The diagnostic criterion of nuclear size at least 6 times normal is ambiguous as size could refer to either nuclear area or diameter. If area, then this criterion could be re-defined as nuclear diameter at least three times normal as it is difficult to visually compare area of nuclei. ^[20] It is also unclear whether IDCP could also include tumors with ductal morphology. ^[20] There is no consensus whether pure IDCP in needle biopsies should be managed with re-biopsy or radical therapy. A pragmatic approach would be to recommend radical therapy only for extensive pure IDCP that is morphologically unequivocal for high-grade prostate cancer. ^[20] Active surveillance is not appropriate when low-grade invasive cancer is associated with IDCP, as such patients usually have unsampled high-grade prostatic adenocarcinoma. ^[20] It is generally recommended that IDCP component of IDCP-inv should be included in tumor extent but not grade. ^[20] However, there are good arguments in favor of grading IDCP associated with invasive cancer. ^[20] WHO 2016 recommends that IDCP should not be graded, but it is unclear whether this applies to both pure IDCP and IDCP-inv. ^[20]

• 
  Intraductal carcinoma of the prostate with an infiltrative growth pattern may be morphologically difficult to distinguish from invasive cancer. One focus shows comedonecrosis (arrow), morphologically suggesting Gleason pattern 5 invasive carcinoma (a haematoxylin and eosin, b CK5/6) ^[20]
• 
  Intraductal carcinoma of the prostate with very patchy basal cells identified by immunohistochemistry. At least some of the glands lacking basal cell immunoreactivity represent intraductal rather than invasive carcinoma (a haematoxylin and eosin, b CK 5/6) ^[20]

Ductal adenocarcinoma may have a prominent cribriforming architecture, with glands appearing relatively round, and may thereby mimic intraductal adenocarcinoma, but can be distinguished by the following features: ^[10]

Further workup

Further workup of a diagnosis of prostate cancer includes mainly:^{[ citation needed ]}

• Gleason score
• Prostate cancer staging

Notes

Reference list

Sources

 This article incorporates text from a free content work.Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0) license.( license statement/permission ).Text taken from adenocarcinoma Prostate adenocarcinoma​ ,Patholines.